This content is machine translated CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes Approximately 30–40% of patients with type 2 diabetes develop chronic kidney disease (CKD) over time. In “landmark” studies such as CREDENCE, DAPA-CKD, EMPA-KIDNEY, and several others, SGLT-2 (sodium-glucose-linked transporter 2)...…
